X4 Pharmaceuticals Inc (NASDAQ: XFOR) kicked off on Tuesday, down -5.80% from the previous trading day, before settling in for the closing price of $0.70. Over the past 52 weeks, XFOR has traded in a range of $0.53-$1.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -20.00%. While this was happening, its average annual earnings per share was recorded 80.70%. With a float of $117.62 million, this company’s outstanding shares have now reached $167.43 million.
Considering the fact that the conglomerate employs 93 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 69.97%, operating margin of -3411.51%, and the pretax margin is 489.32%.
X4 Pharmaceuticals Inc (XFOR) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of X4 Pharmaceuticals Inc is 30.19%, while institutional ownership is 38.56%. The most recent insider transaction that took place on Mar 11 ’24, was worth 12,552. In this transaction Chief Scientific Officer of this company sold 14,235 shares at a rate of $0.88, taking the stock ownership to the 234,301 shares. Before that another transaction happened on Mar 11 ’24, when Company’s President and CEO sold 49,678 for $0.88, making the entire transaction worth $43,856. This insider now owns 765,068 shares in total.
X4 Pharmaceuticals Inc (XFOR) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 80.70% per share during the next fiscal year.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) Trading Performance Indicators
Take a look at X4 Pharmaceuticals Inc’s (XFOR) current performance indicators. Last quarter, stock had a quick ratio of 6.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 198.41.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.09, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.46 in one year’s time.
Technical Analysis of X4 Pharmaceuticals Inc (XFOR)
Compared to the last year’s volume of 2.32 million, its volume of 0.75 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 22.20%. Additionally, its Average True Range was 0.06.
During the past 100 days, X4 Pharmaceuticals Inc’s (XFOR) raw stochastic average was set at 14.94%, which indicates a significant decrease from 38.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.13% in the past 14 days, which was lower than the 100.70% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7153, while its 200-day Moving Average is $0.9038. Nevertheless, the first resistance level for the watch stands at $0.7137 in the near term. At $0.7679, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.8059. If the price goes on to break the first support level at $0.6215, it is likely to go to the next support level at $0.5835. Should the price break the second support level, the third support level stands at $0.5293.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) Key Stats
The company with the Market Capitalisation of 111.11 million has total of 167,938K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -101,170 K annual income. Company’s last quarter sales were recorded 560 K and last quarter income was 90,830 K.
